Clinical Trial Update: Study of Antithymocyte Globulin for Treatment of New-onset T1DM [Phase 2]

View source ↗

Summary

Phase 2 trial of Antithymocyte Globulin for new-onset Type 1 diabetes mellitus was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: New-onset Type 1 Diabetes Mellitus | Phase 2 | Status: TERMINATED | Results posted: 2014-04-21